Screening and follow-up of patients with Rheumatic Diseases and Rheumatological Treatments Infected with Trypanosoma cruzi (American Tryppanosomiasis or Chagas?s Disease). Is it possible a Reactivation?

RINGER A; RUFFINO J; CUADRANTI N; ROLLA I; VANDALE J; ACHILLI C; ARGENTO C; MARTINEZ F; CORTESE N; PALATNIK M; LAGRUTTA M; LEIVA R; AGUILA D; SVETAZ M; CORDOBA L; ZAFRA M; GAMBANDER T; SCIARRATA P; VILLAR S; GONZALEZ F; PACINI F, M; PEREZ A; BOTTASSO O; ABDALA MARCE

Atlanta

Congreso; The 2019 ACR/ARP Annual Meeting; 2019

American Trypanosomiasis or Chagas Disease (CD) is a zoonotic infection, endemic in Latin America. It is a major cause of morbidity, mortality and economic burden in developing countries. Because of population movements, it has spread out around the globe. CD behavior has been well-described in patients with HIV infection, oncologic and organ transplant-related immunosuppression, but little is known in rheumatic diseases (RD) with rheumatologic treatments (RT).The purpose of this research is to screen and follow up (clinical and serologically) patients with RD under RT, with concomitant CD. To detect clinical and serological reactivation.